Lactobacillus leichmannii

Bacteria
General | Carbohydrate O/F | Substrate utilisation | Enzymes | Metabolites | Antibiotics

Overview

  • Lactobacillus leichmannii is a Gram-positive, non-spore-forming, facultatively anaerobic, non-motile, rod-shaped bacterium. It has been detected in at least 5 gut microbiome compilation studies or metastudies. Lactobacillus leichmannii is probably a rare gut coloniser.



  • This organism has been recovered from human faeces. The risk classification (www.baua.de) for this organism is 1, i.e., low risk of infection and spread. Pathogenicity status unknown, or very unlikely to be pathogenic. Likely to be transient and not a long-term gut commensal. Robust growth can have positive consequences for gut health.
    • GENERAL CHARACTERISTICS
    Character Response
  • ±
  • Strain-dependent hydrolysis or digestion:
  • arginine;
  • H+
  • Acid from carbohydrates usually produced:
  • fructose; glucose; amygdalin; aesculin; cellubiose; maltose; sucrose;
  • ±
  • Strain-dependent acid from carbs:
  • lactose; trehalose;
    • SPECIAL FEATURES
    Character Response
  • ✗
  • Metabolites not produced:
  • H₂S; indole;
  • ✗
  • NO3➔NO2:
  • not reduced
    • RESPONSE TO ANTIBIOTICS (Citron2012); (Goldstein2006); (Goldstein2005);
    Class Active Resistant
  • Penicillins:
  • ampicillin; ampicillin-sulbactam; imipenem; piperacillin-tazobactam;
  • Macrolides:
  • pristinamycin; quinupristin-dalfopristin;
  • Quinolines:
  • levofloxacin; moxifloxacin;
  • Vancomycins:
  • vancomycin;
  • Miscellaneous antibiotics:
  • clindamycin; linezolid; pristinamycin;

  • Moore, WEC & LV Holdeman (1974). Human fecal flora: the normal flora of 20 Japanese-Hawaiians. Appl. Microbiol. 27: 961-979.

    • Details

    GENERAL
    Lineage Physiology General Growth Tolerances Hydrol./digest./degr.
    Phylum:  Firmicutes Class:  Bacilli Order:  Lactobacillales Family:  Lactobacillaceae Genus:  Lactobacillus Gram stain:  + O2 Relation.:  facultatively anaerobic Spore:  No spore Motility:  Sessile Morphology:  Rod
    Health:   Positive
    Source:  human faeces
    		Gelatin:  neg Casein:  neg Arginine:  d
    CARBOHYDRATE ACID FORMATION
    Monosaccharide O/F Oligosaccharide O/F Polysaccharide O/F Polyol O/F Other O/F
    Arabinose:  neg Fructose:  + Galactose:  neg Glucose:  + D-Lyxose:  neg Rhamnose:  neg Ribose:  neg Cellubiose:  + Lactose:  d Maltose:  + Melezitose:  neg Melibiose:  neg Sucrose:  + Trehalose:  d Amygdalin:  + Aesculin:  + Mannitol:  neg Sorbitol:  neg Gluconate:  neg
    ENZYME ACTIVITY
    Enzymes: General Enzymes: Carbohydrate Enzymes: Protein Enzymes: Arylamidases Enzymes: Esters/fats
    Catalase:  neg
    METABOLITES - PRODUCTION & USE
    Fuel Usable Metabolites Metabolites Released Special Products Compounds Produced

    		H2S:  neg Indole:  neg
    ANTIBIOTICS ℞
    Penicillins & Penems (μg/mL) Cephalosporins (μg/mL) Aminoglycosides (μg/mL) Macrolides (μg/mL) Quinolones (μg/mL)
    ampicillin:  S(MIC50): 0.128, MIC90: 0.5, RNG: (0.03-1)
    amp-sulb:  S(MIC50): 0.125, MIC90: 0.5, RNG: (0.06–1)
    piper-taz:  S(MIC50): 0.25, MIC90: 1, RNG: (0.03-1)
    imipenem:  S(MIC50): 0.06, MIC90: 0.25, RNG: (0.03-1)
    cefoxitin:  Var(MIC50): 8, MIC90: >128, RNG: (0.25–>128)
    clarithromycin:  Var(MIC50): 0.25, MIC90: >64, RNG: (0.03–>64)
    pristinamycin:  S(MIC50): 0.12, MIC90: 0.25, RNG: (0.03–2)
    quin-dalf:  S(MIC50): 0.25, MIC90: 1, RNG: (0.125-4)
    telithromycin:  Var(MIC50): 0.06, MIC90: >32, RNG: (0.03->32)
    linezolid:  S(MIC50): 4, MIC90: 8, RNG: (1-8)
    levofloxacin:  S(MIC50): 2, MIC90: 8, RNG: (0.25–>16)
    moxifloxacin:  S(MIC50): 1, MIC90: 2, RNG: (0.25–2)
    Tetracyclines (μg/mL) Vancomycin Class (μg/mL) Polypep/ketides (μg/mL) Heterocycles (μg/mL) Other (μg/mL)
    vancomycin:  S(MIC50): 1, MIC90: 4, RNG: (0.25-8)
    metronidazole:  Var(MIC50): 1, MIC90: >32, RNG: (0.25–>32)
    clindamycin:  S(MIC50): 0.5, MIC90: 4, RNG: (0.03->32)
    daptomycin:  Var(MIC50): 4, MIC90: >32, RNG: (0.25->32)

    References

    SPECIFIC REFERENCES FOR LACTOBACILLUS LEICHMANNII
  • Citron2012 - In vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species.
  • Goldstein2006 - In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections.
  • Goldstein2005 - Comparative in vitro activities of XRP 2868, pristinamycin, quinupristin-dalfopristin, vancomycin, daptomycin, linezolid, clarithromycin, telithromycin, clindamycin, and ampicillin against anaerobic gram-positive species, actinomycetes, and lactobacilli.
  • ...............................
    • GUT MICROBIOME COMPILATIONS AND METASTUDIES FOR LACTOBACILLUS LEICHMANNII
  • Finegold1977 - Fecal microbial flora in Seventh Day Adventist populations and control subjects.
  • Holdeman1976 - Human fecal flora: variation in bacterial composition within individuals and a possible effect of emotional stress.
  • Lagier2016 - Culture of previously uncultured members of the human gut microbiota by culturomics.
  • Moore1974 - Human fecal flora: the normal flora of 20 Japanese-Hawaiians.
  • RajilicStojanovic2014 - The first 1000 cultured species of the human gastrointestinal microbiota.
  • ...............................
    • GENERAL REFERENCES FOR LACTOBACILLUS LEICHMANNII
  • Ludwig2009 - Revised road map to the phylum Firmicutes.
    • Added: April 08, 2021